Picture of CSL logo

CSL CSL Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m+1.47%
3m-4.48%
6m+10.43%
1yr-1.35%
Volume Change (%)
10d/3m-3.09%
Price vs... (%)
52w High-1.93%
50d MA+5.77%
200d MA+8.15%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)35.49
PEG Ratio (f)4.33
EPS Growth (f)8.92%
Dividend Yield (f)1.27%
Valuation (ttm)IndustryMarket
Price to Book Value6.79
Price to Tang. Book8.29
Price to Free Cashflow71.7
Price to Sales9.38
EV to EBITDA28.31

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital13.78%
Return on Equity19.64%
Operating Margin27.72%

Financial Summary

Year End 30th JunUnit201820192020202120222023E2024ECAGR / Avg
Total Revenue$m7,915.38,538.69,150.810,31010,561.913,081.4514,654.158.82%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+39.93+11.47+8.39+15.8-5.62-4.19+27.26n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202330th Jun 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of CSL EPS forecast chart

Profile Summary

CSL Limited (CSL) is a biotechnology company engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. CSL provides a portfolio of life saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Its segments include CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. CSL’s products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.

Directors

Last Annual
June 30th, 2022
Last Interim
June 30th, 2022
Incorporated
April 1st, 1991
Public Since
June 8th, 1994
No. of Shareholders
241,985
No. of Employees
30,000
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
481,706,266

CSL Share Price Performance

Upcoming Events for CSL

Half Year 2023 CSL Ltd Earnings Release

Similar to CSL

Picture of Acrux logo

Acrux

au flag iconAustralian Stock Exchange - SEATS

Picture of AFT Pharmaceuticals logo

AFT Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

Picture of Auscann group logo

Auscann group

au flag iconAustralian Stock Exchange - SEATS

Picture of Biome Australia logo

Biome Australia

au flag iconAustralian Stock Exchange - SEATS

Picture of Botanix Pharmaceuticals logo

Botanix Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

FAQ

Or unlock with your email

Or unlock with your email